| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-726
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2018-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2020-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2020531635-A |
| titleOfInvention |
Combination of MAPK / ERK pathway inhibitors and glycosaminoglycans for the treatment of cancer |
| abstract |
The present invention is a negatively charged glycosaminoglycan for use as a pharmaceutical for the treatment of cancer, including combined administration of a negatively charged glycosaminoglycan and an inhibitor of the MAPK / ERK pathway. , This glycosaminoglycan relates to a negatively charged glycosaminoglycan characterized by the absence of the terminal pentasaccharide of heparin. The present invention also includes the combined administration of glycosaminoglycan and a MAPK / ERK pathway inhibitor as a medicament for the treatment of cancer types that are resistant to MAPK / ERK pathway inhibitor treatment alone. [Selection diagram] Fig. 1 |
| priorityDate |
2017-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |